Results 151 to 160 of about 825,057 (283)
Screening for atrial fibrillation according to serum thyroid-stimulating hormone: an opportunity for refinement? [PDF]
Mavilakandy AK, Lip GYH.
europepmc +1 more source
Results of oral TRH test in the differentiation of compensated and decompensated autonomous thyroid nodules [PDF]
Büll, U. +2 more
core +1 more source
Abstract Background NKX2‐1–related disorders (NKX2‐1‐RDs) classically present with a triad of neurological, endocrine, and pulmonary manifestations, including benign hereditary chorea. However, in a fraction of patients, NKX2‐1 coding variants are not detected, and variants outside the NKX2‐1 locus have been reported.
Robin Wijngaard +33 more
wiley +1 more source
Thyroid stimulating hormone (TSH): does it live up to its promises in the andrology laboratory? [PDF]
Alizadeh Moghadam Masouleh A +6 more
europepmc +1 more source
ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee +2 more
wiley +1 more source
A case of inappropriate thyroid-stimulating hormone secretion syndrome after thalidomide treatment. [PDF]
Zhu Y, Chen J.
europepmc +1 more source
Abstract The American Thyroid Association (ATA) has published an update to the 2015 management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer (DTC). This updated version focuses solely on the management of differentiated thyroid cancer, offering a comprehensive set of guidelines for all stakeholders in the care of ...
Chau Nguyen +2 more
wiley +1 more source
Anaesthesia at the edge: Thyroid stimulating hormone >100 µIU/mL in time-sensitive surgery. [PDF]
Jain N, Chincholi IH.
europepmc +1 more source
Abstract Objective About 20% of thyroid nodules detected on ultrasound are cytologically indeterminate (Bethesda categories III and IV), but the rate of malignancy of these nodules is less than 36%. The ability of Afirma Genomic Sequencing Classifier (GSC) to further risk‐stratify indeterminate thyroid nodules among Black and Hispanic patients is ...
Peter J. Attia +5 more
wiley +1 more source

